G factor (GM-CSF) is a hematopoietic cytokine that stimulates proliferation, differentiation, and functional activity of granulocytic and monocytic cell lines or mature cells, respectively. These properties suggest possible beneficial effects of GM-CSF in states of myelosuppression and impaired host defense, and a number of therapeutic expectations have been fulfilled in recent clinical s t~d i e s .~.~ However, our understanding of the mechanism of action of GM-CSF is still incomplete.
The action of GM-CSF involves generation of lipid mediators. From investigations in vitro it is known that the cytokine stimulates leukotriene (LT) biosynthesis in eosinophils and neutrophkiX2 LTs and their inhibitors have further been shown to modulate CSF-induced clonal growth of granulocyte-macrophage progenitor cells. ','-' The impact of LTs in GM-CSF action is of great interest as LT biosynthesis and action are accessible to specific pharmacologic intervention.*-"
We demonstrated recently that GM-CSF enhances LT biosynthesis in vivo in patients suffering from cytopenia induced by cytostatic drugs or from myelodysplastic syndrome." However, these disorders affect the bone marrow, the primary target for GM-CSF action. In the resulting pathophysiologic situations, distinct changes in the activities of several cytokines must be expected, making it difficult to interpret the action of exogenously added GM-CSF. Also, the appearance of adverse effects of the cytokine may be altered or disguised by an underlying disease.
The present study was conducted in healthy volunteers t o overcome these problems. Two different preparations of human recombinant GM-CSF were compared glycosylated GM-CSF derived from Chinese hamster ovary carcinoma (CHO) cells (molecular mass, 14 to 32 Kd) and GM-CSF from Escherichia coli that is lacking glycosyl residues ( I 4 Kd). Direct comparison of the two GM-CSF preparations enables estimation of the impact of the carbohydrate moiety injection of GM-CSF from E coli, serum concentrations increased and decreased more rapidly and reached a 2.3-fold higher maximum compared with GM-CSF from CHO. GM-CSF induced a biphasic change in leukocyte counts that proceeded considerably faster after the E coli preparation than after GM-CSF from CHO. The urinary leukotriene concentration increased 1.3-to 14-fold or 2.1 -to 44-fold after the administration of GM-CSF from CHO or Ecoli, respectively. Urinary leukotriene concentrations correlated significantly with the maximum of basophil counts and correlated with the occurrence of some adverse reactions, ie, flu-like symptoms, bone pain, or dyspnoea. Our data confirm the conception that leukotrienes may play a significant role in GM-CSF action in vivo. They especially direct attention to the possible relevance of leukotrienes to untoward effects of GM-CSF treatment. in GM-CSF action. This may be of interest because native GM-CSF appears in a variety of forms that differ by the amount of glyc~sylation~.~ and because either glycosylated or nonglycosylated GM-CSF have been used in previous studies. 3 3 4~1 2 4 5 The effects of the two GM-CSF preparations on the endogenous LT production in association with pharmacokinetic parameters and biologic effects will be presented.
MATERIALS AND METHODS

Volunteers.
The study was conducted with 2 I healthy male individuals without any evidence of disease from anamnestic exploration, physical, or laboratory examination. The age range was 20 to 38 years (median, 28 years). The weight range was 58.0 to 87.1 kg (median, 76.4 kg). Seven volunteers were randomly selected for treatment with GM-CSF from CHO, 14 individuals were treated with GM-CSF from E coli.
Recombinant human GM-CSF from CHO and recombinant human GM-CSF from E coli was provided by Sandoz Ltd (Basel, Switzerland). Whereas expression of GM-CSF in CHO cells results in glycosylation of the molecule and molecular masses of 14 to 32 Kd, GM-CSF from E coli is devoid of glycosyl residues and has a molecular mass of 14 Kd. Quantitative specifications of GM-CSF dose or of GM-CSF serum concentrations will be given on 
-
DENZLINGER ET AL a molar basis throughout this report. GM-CSF from CHO or E coli, respectively, was injected subcutaneously into the deltoid region of one upper arm at a dose of 0.7 nmol (corresponding to 10 pg pure protein) per kilogram of body weight.
Venous blood samples were taken twice before GM-CSF administration for determination of basal values of GM-CSF and blood cell counts. After the injection of GM-CSF, blood sampling was repeated at intervals of 10 minutes for the first 30 minutes. Thereafter, blood samples were collected every hour for 8 hours, followed by 2-to 4-hour intervals for another 8 hours and 8-hour intervals for 32 hours. Additional blood samples were collected at 96 and at 336 hours after GM-CSF administration. Urine was obtained from spontaneous micturition before GM-CSF and sampled 0 to 24 hours and 24 to 48 hours after administration ofthe cytokine. Urine was stored at -30°C until analysis. Urine samples were screened (Combur9Test; Boehringer, Mannheim, Germany) for pathologic constituents (leukocytes, erythrocytes, protein, etc). Creatinine concentrations in urine were determined by the J a E reaction.
GM-CSF serum concentrations were determined using a two-antibody sandwich enzyme-linked immunoassay developed at the Sandoz Pharma Laboratories (Basel, Switzerland). The assay system consisted of a murine monoclonal anti-GM-CSF antibody raised against GM-CSF from CHO and an anti-GM-CSF antiserum raised by injection of GM-CSF from E coli in a mountain sheep. GM-CSF from the serum samples was fixed to solid phase by the monoclonal antibody and quantitated by binding of the biotinylated sheep antiserum and subsequent addition of alkaline phosphatase conjugated to streptavidin. The lower detection limit of the assay was at 10 fmol GM-CSF/mL serum both for GM-CSF from CHO and for GM-CSF from E coli. No cross-reactivities were observed using up to 10 ng of granulocyte-CSF (G-CSF), Interleukin-3 (IL-3), IL-4, or IL-6, respectively.
LT analysis was performed by sequential use of high-performance liquid chromatography (HPLC) and radioimmunoassay (RIA) as recently described in detail," with a few minor modifications. Briefly, urine was deproteinized by storage in 80% methanolic solution at -40°C and subsequent centrifugation at 8,0008. HPLC of deproteinized urine samples was performed on a C18 Hypersil column (4.6 X 250 mm, 5 pm particles; Shandon, Runkorn, UK) with a CIS precolumn (Waters, Milford, MA). The mobile phase consisted of methanol, water, acetic acid (65:35:0.1 by volume), 1 mmol/L EDTA, pH 5.6, adjusted with ammonium hydroxide. The flow rate was 1 mL/min. The RIA was performed in the fractions coeluting with standard ['HILTS using a rabbit cysteinyl LT antiserum, kindly donated by Prof B.A. Peskar (Ruhr-UniversitAt, Bochum, Germany). Recovery of LTs from urine was tested routinely by adding defined amounts of standard LTE4 to urine samples followed by processing and analysis by HPLC and RIA as described above. Reproducibility was assayed by replicate determinations in urine samples." LTs and ['HILTS were from commercial sources (Paesel, Frankfurt, Germany: Amersham, Buchnghamshire, UK; or DuPont, Boston, MA, respectively). N-acetyl LTE, and N-acetyl ['HILTE, were synthesized from LTE, and ['HILTE,, as described.16
Student's t-test for paired observations was used to analyze significance of differences between determinations before and after GM-CSF treatment. The t-test for unpaired observations was used to analyze significance of differences between values obtained with GM-CSF from CHO and from E coli. Correlations were estimated by calculating product-moment correlation coefficients and rank correlation coefficients (Spearman).
Ethical approval for the GM-CSF treatment studies was obtained from the Ethics Committee, Munchen, incorporated.
Sample collection.
GM-CSF serum concentrations.
LT analysis.
Statistics.
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RESULTS
GM-CSF pharmacokinetics and hematologic effects.
Before GM-CSF administration, GM-CSF serum concentrations were below the detection limit of the assay system, ie, below 10 fmol/mL serum. Seven volunteers were treated with a subcutaneous injection of GM-CSF from CHO at a dose of 0.7 nmol/kg body weight; 14 volunteers were treated in the same way with GM-CSF from E coli. The increase and the decrease in GM-CSF serum concentration were more rapid after GM-CSF from E coli compared with GM-CSF from CHO (Fig 1) . After GM-CSF from CHO, maximum GM-CSF serum concentrations were obtained at 7.6 k 2.7 hours and resulted in 221 k 100 pmol GM-CSF/L serum (mean f SD, n = 7). After GM-CSF from E coli, maximum GM-CSF serum concentrations were determined already at 3.9 -t 1.3 hours and resulted in 514 f 136 pmol GM-CSF/L serum (n = 14). However, due to a more sustained increase in GM-CSF serum concentration, the area under the serum concentration-time curve obtained after GM-CSF from CHO (3.35 k 1.03 nmol/L X hour, mean f SD, n = 7) was not significantly different from the area determined after GM-CSF from
The hematologic effects of GM-CSF were characterized by biphasic changes in leukocyte counts. During the first hour after injection of GM-CSF, leukocyte counts declined to about one-third of the counts before treatment (Fig 2) . Values returned to the original level within 3 or 4 hours after GM-CSF from E coli or CHO, respectively. Maximum leukocyte concentrations were determined 11 or 27 hours after the respective GM-CSF preparation. They were about 2.4-fold higher than pretreatment values. The changes in leukocyte counts occurred significantly faster after GM-CSF from E coli. Leukocyte counts remained elevated for a significantly longer period of time after GM-CSF from CHO (Fig 2) .
The biphasic shape of leukocyte concentrations was determined mainly by changes in the number of neutrophils, which almost disappeared in the first phase after GM-CSF and which strongly increased in the second phase together with a shift to the left. However, monocyte and eosinophil counts also declined initially and markedly increased together with basophil counts during the second day after GM-CSF. Monocytes increased to 328% t 259% (mean k SD, n = 7) or 243% ? 177% (n = 14) of pretreatment values after GM-CSF from CHO or E coli, respectively. Maximum eosinophil counts were 477% f 177% (n = 7) or 320% f 156% (n = 14) of pretreatment values; maximum basophil counts were 143 f 83 M/L (n = 7) or 91 f 79 M/L (n = 14) after GM-CSF from CHO or E coli, respectively. Before treatment with GM-CSF, healthy volunteers secreted I. 1 to 28 (mean, 9.9) nmol LTE, plus LTE4NAc/mol creatinine (Fig 3) , as determined by combined use of HPLC and RIA. LTE4NAc constituted a minor, yet significant component amounting up to 36% (mean, 13%) of LTE4. The concentrations in urine of LTC, and LTD4 were below the detection limit of our assay system, ie, below 50 pmol/L. There was a close relation between the urinary LTE, plus LTE4NAc concentration corrected for the urinary creatinine concentration and the arl:-ount of LTE, plus LTE4NAc secreted per day. On the average, 1 nmol LTE, plus LTE4NAc in urine per mole creatinine corresponded to 14 (range, 12 to 18) pmol LTE, plus LTE,NAc secreted per 24 hours. The respective product moment correlation coefficient ranged from 0.9 1 to 0.99 in the healthy volunteers.
During the first 24 hours after the injection of GM-CSF, urinary cysteinyl LTs increased 1.3-to 14-fold or 2.1 -to 44-fold in volunteers treated with GM-CSF from CHO or E coli, respectively (Fig 3) , resulting in urinary LT concentrations of 32 f 26 or 16 1 f 124 nmol LTE4 plus LTE4NAc/mol creatinine (mean k SD). Enhancement of urinary cysteinyl
LTs was statistically significant (P < .001) with both GM-CSF preparations, but GM-CSF from E coli was significantly (P < .01) more effective in this respect. Twenty-four hours after administration of GM-CSF from CHO, urinary cysteinyl LTs returned to pretreatment values (10 -+ 9 nmol LTE, plus LTE4NAc/mol creatinine, mean f SD), whereas they were still significantly elevated after GM-CSF from E coli (52 f 35 nmol LTE, plus LTE,NAc/mol creatinine; P < .01). There were no significant changes in the proportions of urinary LTE, and LTE4NAc after GM-CSF administration. Association of urinary cysteinyl LTs with pharmacokinetic parameters of GM-CSF. The higher concentrations of urinary cysteinyl LTs obtained after GM-CSF from E coli ( Fig  3) were associated with earlier and higher peak serum con-
Efect of GM-CSF on urinary cysteinyl LTs.
T i m e after GPI-CSF [ h l centrations of GM-CSF as compared with GM-CSF from CHO (Fig 1) . However, there were no statistically significant correlations between individual pharmacokinetic parameters (GM-CSF maximum serum concentration, serum half life, area under the serum concentration-time curve) and individual changes in urinary cysteinyl LTs in the volunteers treated with GM-CSF from CHO or E coli, respectively (the product moment correlation coefficients ranged from -0.2 to 0.3).
Association of urinary cysteinyl LTs with hematologic e$ fects of GM-CSF. Urinary cysteinyl LT concentrations and their relative changes after GM-CSF administration were tested for correlation with the cytokine's effects on total leukocytes, neutrophils, monocytes, eosinophils, basophils, bands, and youngs. There was a significant positive correlation between the LT concentrations in the urine sampled during the first 24 hours after GM-CSF administration and the maximum basophil counts with both the CHO and the E coli GM-CSF preparations. The corresponding product moment correlation coefficients were 0.85 and 0.70, respectively (Fig  4) . Correlations of urinary cysteinyl LTs and maximum basophil counts differed with respect to their slopes in the groups of volunteers treated with GM-CSF from CHO or E coli. A similar increase in basophil counts in volunteers treated with either GM-CSF preparation was paralleled by significantly higher urinary LTs in the group of individuals treated with GM-CSF from E coli (Fig 4) .
No consistent correlations between urinary cysteinyl LTs and hematologic parameters other than basophils were found in the healthy volunteers. Product moment correlation coef- Absence of adverse effects was associated with low urinary cysteinyl LTs. Flu-like symptoms, including a transient increase in body temperature, nasal congestion and catarrh, pharyngeal irritation, conjunctival redness and congestion were observed in 10 of the 21 (48%) volunteers. They were virtually absent in the low LT producers and increased in frequency with increasing urinary cysteinyl LTs. Bone pain was felt in the area of the lumbar and/or thoracic spine and/ or in the sternum. It was characterized as tenderness, as a feeling of pressure, or as pulsating pain. Eight of the 2 1 (38%) volunteers complained of bone pain. It was most frequent in the high LT producers. Dyspnoea was reported as difficulty of breathing, mainly expiratory. Wheezes and coarse rhonchi were heard during auscultation. Dyspnoea may thus be classified as an asthmatic response. The two volunteers suffering from this adverse effect had been treated with GM-CSF from E coli and had high urinary cysteinyl LT concentrations. Gastrointestinal symptoms included nausea, vomiting, ab- For personal use only. on October 30, 2017. by guest www.bloodjournal.org From domina1 pain, and diarrhea. Thirty-eight percent of the volunteers complained of these symptoms. There was no obvious relation of gastrointestinal symptoms with urinary cysteinyl LTs. Skin reactions included erythema, scattered pustulation, or pustular eruption at the injection site. These symptoms were observed in 48% of the volunteers. They also do not seem to be related to increased urinary LTs. Arthralgia in the olecranon and knee joints combined with pain in neighboring muscles occurred in one volunteer treated with GM-CSF from E coli. The LT generation was ranked intermediate in this individual.
Some volunteers suffered from more than one adverse effect. Combinations of up to four untoward effects were observed without a detectable interrelation. Some participants had additional complaints of mild to moderate headache, tiredness, heat sensations, or feeling of cold extremities. However, the relation of these latter symptoms to GM-CSF treatment was uncertain.
DISCUSSION
In the present study, we demonstrated that GM-CSF activates the endogenous LT production in healthy volunteers. Urinary LTE, plus LTE,NAc corrected for urinary creatinine was used as a measure for the endogenous LT biosynthesis. Because in some individuals a significant portion of LTE, may be acetylated to LTE,NAC,~','~ determination of both LTE, plus LTE,NAc appears to be superior to determination of LTE, alone for a survey of the generation of these lipid mediators. LTE4 in urine is by now widely accepted as a parameter for the endogenous LT prod~ction.",'~-~~ The close correlation between urinary LT concentrations corrected for urinary creatinine and the renal LT elimination rate confirms earlier observation^,'^ suggesting that the renal elimination of LTs proceeds via glomerular filtration without appreciable secretion or reabsorption.
Data obtained in vitro suggest that GM-CSF is not a direct stimulator of LT production, but rather primes leukocytes for enhanced LT production elicited by succeeding If this is the case, our results suggest that such stimuli are constitutively present or concomitantly induced by GM-CSF administration, not only in cytopenic or myelodysplastic patients," but also in healthy volunteers (Fig 3) .
Our results encourage speculations on causal relations between hematologic effects, adverse reactions, and the elevation of endogenous LTs after GM-CSF administration. Indeed, LTs may play a role in both aspects of GM-CSF action.
LTs may be involved in the proliferative response to GM-CSF, as LTs and LT inhibitors have been shown to modulate the proliferation of myeloic progenitor cells and malignant blasts in vitro.1,5-7,26,27 In cytopenic patients, a lineary correlation was found between the increase in total leukocyte counts and the increase in urinary LTs after GM-CSF administration." The corresponding correlation was not statistically significant in the present study in healthy volunteers who had normal blood cell counts before treatment with the cytokine. However, a more rapid increase in leukocyte counts (Fig 2) was associated with a higher LT production (Fig 3) in the volunteers treated with GM-CSF from E coli as compared with those treated with GM-CSF from CHO. This may be interpreted as an argument for a role of LTs in the proliferative response after GM-CSF administration in vivo.
LTs may also be involved in the GM-CSF-induced stimulation of leukocytes. The initial decrease in leukocyte counts to about one-third of pretreatment values (Fig 2) is most likely caused by activation of leukocytes. This effect was found to be associated with an upregulation of adhesion molecules, promoting adherence of leukocytes to the blood vessel LTs induce leukocyte adhesion to endothelial cells via the same type of adhesion molecules (CD1 1/CD18)28329 and leukocyte adhesion can be antagonized by LT biosynthesis inhibitors as demonstrated in a model of reperfusion injury.3o It seems possible, therefore, that the GM-CSF-induced initial decrease in leukocyte counts is mediated by LTs.
Functional activation of leukocytes, including increased generation of LTs, may also explain some of the adverse effects caused by GM-CSF. After GM-CSF treatment, a significant positive correlation was found between the urinary cysteinyl LTs and the basophils (Fig 4) , which are known to be central components in hypersensitivity reactions. A positive relation was also found between enhanced LT production and flu-like symptoms, bone pain, or asthmatic reactions (Fig 5) . Flu-like symptoms associated with enhanced vascular permeability and inflammatory reactions in mucous membranes might well be explained by known actions of LTs.~',~* Involvement of LTs in asthmatic responses is widely accepted.8-'o. '8.19~31~32 No obvious correlation was observed between GM-CSF-induced LT production and gastrointestinal symptoms or skin reactions (Fig 5) .
Comparison of the effects of the two different GM-CSF preparations showed several differences. Structurally, GM-CSF from E coli differs from GM-CSF from CHO in the absence of glycosyl residue^.^,^ Pharmacokinetic consequences of this difference were a more rapid increase and decrease in serum concentration and a higher maximum serum concentration of GM-CSF from E coli (Fig 1) . The data demonstrated are in line with results derived from a larger number of healthy volunteers (R. Pokorny et al, unpublished observations). Differences in the pharmacokinetics between glycosylated and nonglycosylated GM-CSF also appear likely when results from recent studies using either preparation are ~o m p a r e d . '~~'~, '~ Pharmacodynamic consequences of the differences between the two GM-CSF preparations were a faster increase and a faster decrease in leukocyte counts (Fig 2) , higher urinary cysteinyl LTs (Fig 3) , and a different pattern of side effects (Fig 5 ) after administration of GM-CSF from E coli compared with GM-CSF from CHO. GM-CSF from CHO caused a number of pathologic skin reactions, whereas the other side effects (flu-like symptoms, bone pain, dyspnoea, gastrointestinal symptoms) clearly predominated in the volunteers treated with GM-CSF from E coli (Fig 5) .
Our results suggest that differences in pharmacokinetics between the two GM-CSF preparations may explain some of the differences in their pharmacodynamics: a more sustained increase in serum GM-CSF after GM-CSF from CHO (Fig 1) corresponded to a more sustained increase in leukocyte counts (Fig 2) ; a higher maximum GM-CSF serum concentration after GM-CSF from E coli (Fig 1) corresponded to a higher LT production (Fig 3) and to more severe side effects (Fig 5) . The GM-CSF dose, route, and velocity of administration are empirical determinants of its t o x i~i t y ,~,~, '~ and the better tolerated GM-CSF from CHO behaves like a prolonged-release form compared with GM-CSF from E coli (Fig 1) .
GM-CSF-induced side effects are usually mild to moderate. However, a case of a capillary leak syndrome and a case of an adult respiratory distress syndrome (ARDS), probably triggered by GM-CSF, have been presented recently.33s34 Involvement of LTs in these pathophysiologic situations is likely. Enhanced vascular permeability resulting in macromolecular leakage is a well-characterized feature of LT act i~n . ' ' .~~ Recent studies on endogenous LT production in ARDS provide additional evidence for a role of leukotrienes in this
Increased leukocyte activity that is associated with enhanced LT biosynthesis and adverse effects is clearly undesirable in healthy individuals and may be dangerous in certain clinical situations. However, a limited increase in LT biosynthesis may be beneficial in immunocompromised patients. Besides a possible involvement in the proliferative response to GM-CSF, enhanced LT biosynthesis may be involved in the upregulation of host defense, including upregulation of immune functions, enhanced antimicrobial activity, and enhanced antitumor cyto~tasis.~~-~' The more pronounced increase in the endogenous LT production after GM-CSF from E coli is, therefore, not necessarily disadvantageous in a therapeutic situation.
Future trials will show whether drugs affecting LT biosynthesis or action can be used to optimize GM-CSF treatment. For personal use only. on October 30, 2017. by guest www.bloodjournal.org From
